The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
Open accessAbstract
To combat future severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and spillovers of SARS-like betacoronaviruses (sarbecoviruses) threatening global health, we designed mosaic nanoparticles that present randomly arranged sarbecovirus spike receptor-binding domains (RBDs) to elicit antibodies against epitopes that are conserved and relatively occluded rather than variable, immunodominant, and exposed. We compared immune responses elicited by mosaic-8 (SARS-CoV-2 and seven animal sarbecoviruses) and homotypic (only SARS-CoV-2) RBD nanoparticles in mice and macaques and observed stronger responses elicited by mosaic-8 to mismatched (not on nanoparticles) strains, including SARS-CoV and animal sarbecoviruses. Mosaic-8 immunization showed equivalent neutralization of SARS-CoV-2 variants, including Omicrons, and protected from SARS-CoV-2 and SARS-CoV challenges, whereas homotypic SARS-CoV-2 immunization protected only from SARS-CoV-2 challenge. Epitope mapping demonstrated increased targeting of conserved epitopes after mosaic-8 immunization. Together, these results suggest that mosaic-8 RBD nanoparticles could protect against SARS-CoV-2 variants and future sarbecovirus spillovers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12
REED, L. J., & MUENCH, H. (1938) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a118408 · Cited by 19,926
Guindon, S., Dufayard, J.-F., Lefort, V., Anisimova, M., Hordijk, W., & Gascuel, O. (2010) · Systematic Biology · doi:10.1093/sysbio/syq010 · Cited by 18,376
Fast, scalable generation of high‐quality protein multiple sequence alignments using Clustal Omega
Sievers, F., Wilm, A., Dineen, D., Gibson, T. J., Karplus, K., Li, W., Lopez, R., McWilliam, H., Remmert, M., Söding, J., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.75 · Cited by 15,355
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Self-citationStarr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956
Self-citationCross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Self-citationStructural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin
Zakeri, B., Fierer, J. O., Celik, E., Chittock, E. C., Schwarz-Linek, U., Moy, V. T., & Howarth, M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115485109 · Cited by 1,662
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599
Self-citationConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures
Landau, M., Mayrose, I., Rosenberg, Y., Glaser, F., Martz, E., Pupko, T., & Ben-Tal, N. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki370 · Cited by 1,413
Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395
Emerging concepts in the science of vaccine adjuvants
Pulendran, B., S. Arunachalam, P., & O’Hagan, D. T. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00163-y · Cited by 1,385
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2022) · Nature · doi:10.1038/s41586-021-04388-0 · Cited by 1,290
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286
Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230
Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · doi:10.1101/2020.12.31.425021 · Cited by 1,178 · cited 1×
“Target list [bead region] were as follows: T helper: GM-CSF [44], IFN gamma [43], IL-1 beta [18], IL-2 [19], IL-4 [20], IL-5 [21], IL-6 [25], IL-8 (CXCL8) [27], IL-10 [28], IL12p70 [34], IL-13 [35], IL-17A (CTLA-8) [36], IL-18 [66], IL-23 [63], TNF alpha [45] Cytokines: CD40L [74], G-CSF (CSF-3) [42], IFN alpha [48],…”
Self-citationGreaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
Self-citationPotent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Gilbert, P. B., Montefiori, D. C., McDermott, A. B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., et al. (2022) · Science · doi:10.1126/science.abm3425 · Cited by 1,137
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., Chadwick, D. R., Clark, R., Cosgrove, C., Galloway, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107659 · Cited by 1,085
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., De Marco, A., di Iulio, J., et al. (2022) · Nature · doi:10.1038/s41586-021-04386-2 · Cited by 1,080
Potently neutralizing and protective human antibodies against SARS-CoV-2
Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2548-6 · Cited by 1,041 · cited 1×
“Target list [bead region] were as follows: T helper: GM-CSF [44], IFN gamma [43], IL-1 beta [18], IL-2 [19], IL-4 [20], IL-5 [21], IL-6 [25], IL-8 (CXCL8) [27], IL-10 [28], IL12p70 [34], IL-13 [35], IL-17A (CTLA-8) [36], IL-18 [66], IL-23 [63], TNF alpha [45] Cytokines: CD40L [74], G-CSF (CSF-3) [42], IFN alpha [48],…”
Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.007 · Cited by 1,016
Self-citationDNA vaccine protection against SARS-CoV-2 in rhesus macaques
Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997
Self-citationHuman Coronavirus: Host-Pathogen Interaction
Fung, T. S., & Liu, D. X. (2019) · Annual Review of Microbiology · doi:10.1146/annurev-micro-020518-115759 · Cited by 960
Winkler, E. S., Bailey, A. L., Kafai, N. M., Nair, S., McCune, B. T., Yu, J., Fox, J. M., Chen, R. E., Earnest, J. T., Keeler, S. P., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0778-2 · Cited by 901 · cited 1×
“Target list [bead region] were as follows: T helper: GM-CSF [44], IFN gamma [43], IL-1 beta [18], IL-2 [19], IL-4 [20], IL-5 [21], IL-6 [25], IL-8 (CXCL8) [27], IL-10 [28], IL12p70 [34], IL-13 [35], IL-17A (CTLA-8) [36], IL-18 [66], IL-23 [63], TNF alpha [45] Cytokines: CD40L [74], G-CSF (CSF-3) [42], IFN alpha [48],…”
Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795
Self-citationCrawford, K. H. D., Eguia, R., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., et al. (2020) · Viruses · doi:10.3390/v12050513 · Cited by 776
Self-citationProspective mapping of viral mutations that escape antibodies used to treat COVID-19
Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D. (2021) · Science · doi:10.1126/science.abf9302 · Cited by 743
Self-citationSensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697
Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis
Zheng, C., Shao, W., Chen, X., Zhang, B., Wang, G., & Zhang, W. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.11.009 · Cited by 693
Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Starr, T. N., Czudnochowski, N., Liu, Z., Zatta, F., Park, Y.-J., Addetia, A., Pinto, D., Beltramello, M., Hernandez, P., Greaney, A. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03807-6 · Cited by 515
Self-citationZost, S. J., Gilchuk, P., Chen, R. E., Case, J. B., Reidy, J. X., Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Chen, E. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0998-x · Cited by 452
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., Cho, A., Agudelo, M., Finkin, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24435-8 · Cited by 433
Self-citationLY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Westendorf, K., Žentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110812 · Cited by 414
Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization
Brune, K. D., Leneghan, D. B., Brian, I. J., Ishizuka, A. S., Bachmann, M. F., Draper, S. J., Biswas, S., & Howarth, M. (2016) · Scientific Reports · doi:10.1038/srep19234 · Cited by 412
Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice
Cohen, A. A., Gnanapragasam, P. N. P., Lee, Y. E., Hoffman, P. R., Ou, S., Kakutani, L. M., Keeffe, J. R., Wu, H.-J., Howarth, M., West, A. P., et al. (2021) · Science · doi:10.1126/science.abf6840 · Cited by 410
Self-citationEvidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia
Wacharapluesadee, S., Tan, C. W., Maneeorn, P., Duengkae, P., Zhu, F., Joyjinda, Y., Kaewpom, T., Chia, W. N., Ampoot, W., Lim, B. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21240-1 · Cited by 403
Zhou, H., Ji, J., Chen, X., Bi, Y., Li, J., Wang, Q., Hu, T., Song, H., Zhao, R., Chen, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.008 · Cited by 380
Approaching infinite affinity through engineering of peptide–protein interaction
Keeble, A. H., Turkki, P., Stokes, S., Khairil Anuar, I. N. A., Rahikainen, R., Hytönen, V. P., & Howarth, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1909653116 · Cited by 379
The antigenic anatomy of SARS-CoV-2 receptor binding domain
Dejnirattisai, W., Zhou, D., Ginn, H. M., Duyvesteyn, H. M. E., Supasa, P., Case, J. B., Zhao, Y., Walter, T. S., Mentzer, A. J., Liu, C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.032 · Cited by 371
Self-citationSeydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.001 · Cited by 364
Ma, X., Zou, F., Yu, F., Li, R., Yuan, Y., Zhang, Y., Zhang, X., Deng, J., Chen, T., Song, Z., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.015 · Cited by 342
Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States
Washington, N. L., Gangavarapu, K., Zeller, M., Bolze, A., Cirulli, E. T., Schiabor Barrett, K. M., Larsen, B. B., Anderson, C., White, S., Cassens, T., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.052 · Cited by 329
Kreer, C., Zehner, M., Weber, T., Ercanoglu, M. S., Gieselmann, L., Rohde, C., Halwe, S., Korenkov, M., Schommers, P., Vanshylla, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.044 · Cited by 309
K18-hACE2 mice develop respiratory disease resembling severe COVID-19
Yinda, C. K., Port, J. R., Bushmaker, T., Offei Owusu, I., Purushotham, J. N., Avanzato, V. A., Fischer, R. J., Schulz, J. E., Holbrook, M. G., Hebner, M. J., et al. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009195 · Cited by 302
Self-citationMosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses
Kanekiyo, M., Joyce, M. G., Gillespie, R. A., Gallagher, J. R., Andrews, S. F., Yassine, H. M., Wheatley, A. K., Fisher, B. E., Ambrozak, D. R., Creanga, A., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0305-x · Cited by 301
Self-citationCompromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality
Zohar, T., Loos, C., Fischinger, S., Atyeo, C., Wang, C., Slein, M. D., Burke, J., Yu, J., Feldman, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.052 · Cited by 297
Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice
Kumari, P., Rothan, H. A., Natekar, J. P., Stone, S., Pathak, H., Strate, P. G., Arora, K., Brinton, M. A., & Kumar, M. (2021) · Viruses · doi:10.3390/v13010132 · Cited by 295
Omicron variant and booster COVID-19 vaccines
Burki, T. K. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00559-2 · Cited by 285
Tan, T. K., Rijal, P., Rahikainen, R., Keeble, A. H., Schimanski, L., Hussain, S., Harvey, R., Hayes, J. W. P., Edwards, J. C., McLean, R. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20654-7 · Cited by 283
Self-citationEngineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination
Bruun, T. U. J., Andersson, A.-M. C., Draper, S. J., & Howarth, M. (2018) · ACS Nano · doi:10.1021/acsnano.8b02805 · Cited by 281
SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse
Konings, F., Perkins, M. D., Kuhn, J. H., Pallen, M. J., Alm, E. J., Archer, B. N., Barakat, A., Bedford, T., Bhiman, J. N., Caly, L., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00932-w · Cited by 276
Self-citationNeutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
Saunders, K. O., Lee, E., Parks, R., Martinez, D. R., Li, D., Chen, H., Edwards, R. J., Gobeil, S., Barr, M., Mansouri, K., et al. (2021) · Nature · doi:10.1038/s41586-021-03594-0 · Cited by 253
Self-citationvan Doremalen, N., Purushotham, J. N., Schulz, J. E., Holbrook, M. G., Bushmaker, T., Carmody, A., Port, J. R., Yinda, C. K., Okumura, A., Saturday, G., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh0755 · Cited by 245
Self-citationKang, Y.-F., Sun, C., Zhuang, Z., Yuan, R.-Y., Zheng, Q., Li, J.-P., Zhou, P.-P., Chen, X.-C., Liu, Z., Zhang, X., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c08379 · Cited by 228
Liu, H., Wu, N. C., Yuan, M., Bangaru, S., Torres, J. L., Caniels, T. G., van Schooten, J., Zhu, X., Lee, C.-C. D., Brouwer, P. J. M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.023 · Cited by 214
ACE2 binding is an ancestral and evolvable trait of sarbecoviruses
Starr, T. N., Zepeda, S. K., Walls, A. C., Greaney, A. J., Alkhovsky, S., Veesler, D., & Bloom, J. D. (2022) · Nature · doi:10.1038/s41586-022-04464-z · Cited by 207
Self-citationA novel SARS-CoV-2 related coronavirus in bats from Cambodia
Delaune, D., Hul, V., Karlsson, E. A., Hassanin, A., Ou, T. P., Baidaliuk, A., Gámbaro, F., Prot, M., Tu, V. T., Chea, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26809-4 · Cited by 195
Walls, A. C., Miranda, M. C., Schäfer, A., Pham, M. N., Greaney, A., Arunachalam, P. S., Navarro, M.-J., Tortorici, M. A., Rogers, K., O’Connor, M. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.015 · Cited by 185 · cited 1×
“Target list [bead region] were as follows: T helper: GM-CSF [44], IFN gamma [43], IL-1 beta [18], IL-2 [19], IL-4 [20], IL-5 [21], IL-6 [25], IL-8 (CXCL8) [27], IL-10 [28], IL12p70 [34], IL-13 [35], IL-17A (CTLA-8) [36], IL-18 [66], IL-23 [63], TNF alpha [45] Cytokines: CD40L [74], G-CSF (CSF-3) [42], IFN alpha [48],…”
Self-citationPowell, A. E., Zhang, K., Sanyal, M., Tang, S., Weidenbacher, P. A., Li, S., Pham, T. D., Pak, J. E., Chiu, W., & Kim, P. S. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01405 · Cited by 182
Dong, W., Mead, H., Tian, L., Park, J.-G., Garcia, J. I., Jaramillo, S., Barr, T., Kollath, D. S., Coyne, V. K., Stone, N. E., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00964-21 · Cited by 182
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
Joyce, M. G., Chen, W.-H., Sankhala, R. S., Hajduczki, A., Thomas, P. V., Choe, M., Martinez, E. J., Chang, W. C., Peterson, C. E., Morrison, E. B., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110143 · Cited by 181
Davidson, A. M., Wysocki, J., & Batlle, D. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15256 · Cited by 180
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
Kleanthous, H., Silverman, J. M., Makar, K. W., Yoon, I.-K., Jackson, N. M., & Vaughn, D. W. (2021) · npj Vaccines · doi:10.1038/s41541-021-00393-6 · Cited by 145
West, A. P., Scharf, L., Horwitz, J. A., Klein, F., Nussenzweig, M. C., & Björkman, P. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309215110 · Cited by 125
Self-citationComparison of Subgenomic and Total RNA in SARS-CoV-2-Challenged Rhesus Macaques
Dagotto, G., Mercado, N. B., Martinez, D. R., Hou, Y. J., Nkolola, J. P., Carnahan, R. H., Crowe, J. E., Baric, R. S., & Barouch, D. H. (2021) · Journal of Virology · doi:10.1128/jvi.02370-20 · Cited by 107
Jette, C. A., Cohen, A. A., Gnanapragasam, P. N. P., Muecksch, F., Lee, Y. E., Huey‐Tubman, K. E., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M. C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109760 · Cited by 105
Self-citationWang, W., Huang, B., Zhu, Y., Tan, W., & Zhu, M. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00643-6 · Cited by 94
Cohen, A. A., Yang, Z., Gnanapragasam, P. N. P., Ou, S. K.-H., Dam, K.-M. A., Wang, H., & Björkman, P. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247963 · Cited by 83
Self-citationNovel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection
Geng, Q., Tai, W., Baxter, V. K., Shi, J., Wan, Y., Zhang, X., Montgomery, S. A., Taft-Benz, S., Anderson, E. J., Knight, A. C., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009897 · Cited by 78
Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine
Li, D., Martinez, D. R., Schäfer, A., Chen, H., Barr, M., Sutherland, L. L., Lee, E., Parks, R., Mielke, D., Edwards, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33985-4 · Cited by 72
Self-citationSARS-like Coronaviruses in Horseshoe Bats (Rhinolophus spp.) in Russia, 2020
Alkhovsky, S. V., Lenshin, S. V., Romashin, A. V., Владимировна, В. Т., Vyshemirsky, O. I., Bulycheva, Y. I., Dk, L., & Gitelman, A. K. (2022) · Viruses · doi:10.3390/v14010113 · Cited by 71
An ACE2-dependent Sarbecovirus in Russian bats is resistant to SARS-CoV-2 vaccines
Seifert, S. N., Bai, S., Fawcett, S., Norton, E. B., Zwezdaryk, K. J., Robinson, J. E., Gunn, B. M., & Letko, M. C. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010828 · Cited by 65
A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy
Greaney, A. J., Starr, T. N., Eguia, R. T., Loes, A. N., Khan, K., Karim, F., Cele, S., Bowen, J. E., Logue, J. K., Corti, D., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010248 · Cited by 62
Self-citationFan, C., Cohen, A. A., Park, M., Hung, A. F.-H., Keeffe, J. R., Gnanapragasam, P. N. P., Lee, Y. E., Gao, H., Kakutani, L. M., Wu, Z., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.019 · Cited by 57
Self-citationBurnett, D. L., Jackson, K., Langley, D. B., Aggarwal, A., Stella, A. O., Johansen, M. D., Balachandran, H., Lenthall, H., Rouet, R., Walker, G. J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.019 · Cited by 45
Vishwanath, S., Carnell, G., Ferrari, M., Asbach, B., Billmeier, M., George, C. L., Sans, M. S., Nadesalingam, A., Huang, C. Q., Paloniemi, M., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01094-2 · Cited by 43
Shinnakasu, R., Sakakibara, S., Yamamoto, H. H., Wang, P.-H., Moriyama, S., Sax, N., Ono, C., Yamanaka, A., Adachi, Y., Onodera, T., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20211003 · Cited by 29
A dynamical study of antibody–antigen encounter reactions
Bongini, L., Fanelli, D., Piazza, F., Rios, P. D. L., Sanner, M. F., & Skoglund, U. (2007) · Physical Biology · doi:10.1088/1478-3975/4/3/004 · Cited by 27
Structural basis of Omicron neutralization by affinity-matured public antibodiesPreprint
Sheward, D. J., Pushparaj, P., Das, H., Kim, C., Kim, S., Hanke, L., Dyrdak, R., McInerney, G. M., Albert, J., Murrell, B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.03.474825 · Cited by 27
dms-view: Interactive visualization tool for deep mutational scanning data
Hilton, S. K., Huddleston, J., Black, A., North, K., Dingens, A. S., Bedford, T., & Bloom, J. D. (2020) · The Journal of Open Source Software · doi:10.21105/joss.02353 · Cited by 26
Self-citationMosa, A. I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02057 · Cited by 20
Hansen, F., Meade-White, K. D., Clancy, C. S., Rosenke, R., Okumura, A., Hawman, D. W., Feldmann, F., Kaza, B., Jarvis, M. A., Rosenke, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110515 · Cited by 17
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice
Walls, A. C., VanBlargan, L. A., Wu, K., Choi, A., Navarro, M. J., Lee, D. W., Avena, L. E., Berrueta, D. M., Pham, M. N., Elbashir, S. M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111299 · Cited by 13
Research works printed but not linked: 3
- D. Yamasoba. Virological characteristics of SARS-CoV-2 BA.2 variant. bioRxiv 480335 [Preprint] (2022); 10.1101/2022.02.14.480335 480335 · DOI
- S. N. Seifert M. C. Letko A sarbecovirus found in Russian bats uses human ACE2. bioRxiv 471310 [Preprint] (2021); 10.1101/2021.12.05.471310 471310 · doi:10.1101/2021.12.05.471310
- J. Heeney. Gene delivery of a single structurally engineered coronavirus vaccine antigen elicits SARS-CoV-2 Omicron and pan-sarbecovirus neutralisation.Research Square 995273 [Preprint] (2021); 10.21203/rs.3.rs-995273/v1 995273 · doi:10.21203/rs.3.rs-995273/v1
Cited by
In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms
Cankat, S., Demael, M. U., & Swadling, L. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-01116-8 · Cited by 84
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Park, Y.-J., Pinto, D., Walls, A. C., Liu, Z., De Marco, A., Benigni, F., Zatta, F., Silacci-Fregni, C., Bassi, J., Sprouse, K. R., et al. (2022) · doi:10.1101/2022.05.08.491108 · Cited by 251
Ruiz, F., Foreman, W. B., Lilly, M., Baharani, V. A., Depierreux, D. M., Chohan, V., Taylor, A. L., Guenthoer, J., Ralph, D., Matsen IV, F. A., et al. (2024) · PLOS Pathogens · doi:10.1371/journal.ppat.1012650 · Cited by 7
Self-citation
Metadata
- Authors
- Cohen, A. A., van Doremalen, N., Greaney, A. J., Andersen, H., Sharma, A., Starr, T. N., Keeffe, J. R., Fan, C., Schulz, J. E., Gnanapragasam, P. N. P., Kakutani, L. M., West, A. P., Saturday, G., Lee, Y. E., Gao, H., Jette, C. A., Lewis, M. G., Tan, T. K., Townsend, A. R., Bloom, J. D., Munster, V. J., & Bjorkman, P. J.
- Venue
- Science
- Published
- 2022-08-05
- Volume
- 377
- Issue
- 6606
- Pages
- eabq0839-eabq0839
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4284689837
- Cited by
- 259
- References
- 91
- FWCI
- 24.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.